Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma.

Matthew Ingham,Shing Mirn Lee,Parag Patwardhan,Edwin Choy,Isan Chen,Shahnaz Singh-Kandah,Lauren Taiclet,Gary K. Schwartz

Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma.

2017

Matthew Ingham
Shing Mirn Lee
Parag Patwardhan
Edwin Choy
Isan Chen
Shahnaz Singh-Kandah
Lauren Taiclet
Gary K. Schwartz

TPS11082Background: Well-differentiated/dedifferentiated liposarcoma (WD/DD LPS) is a sarcoma subtype of adipocytic origin characterized by amplification of cyclin dependent kinase 4 (CDK4) and MDM...

Keywords:

Sitravatinib
Pathology
Receptor tyrosine kinase
Dedifferentiated liposarcoma
Medicine
receptor tyrosine kinase inhibitor
well differentiated
Sarcoma
Cyclin-dependent kinase 4
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations